Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking
Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.
Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test
Psychiatry needs objective diagnostics. Laguna Diagnostics now faces the harder test: proving mRNA biomarkers can scale in real care.
BNB Plus completes record LineaDNA order as strategic review puts LineaRx in sharper focus
BNB Plus completed a record $1.2 million LineaDNA order for LineaRx. Read what it means for scale, margins, strategy, and BNBX stock sentiment.
CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.